NRx Pharmaceuticals, Inc. Email Format

Biotechnology ResearchDelaware, United States11-50 Employees

NRx Pharmaceuticals, Inc. is a biotechnology company based in Wilmington, Delaware, focused on developing therapies for central nervous system disorders with an emphasis on severe mood conditions and PTSD. It pursues preservative-free intravenous ketamine formulations and related neuroplasticity approaches to address unmet medical needs in suicidal depression, suicidal bipolar depression, and PTSD. It has filed an Abbreviated New Drug Application for NRX-100 and begun the process for a full NDA to expand NRX-100's use in suicidal depression. 

Its work centers on NMDA-based strategies, with NRX-101 appearing in its broader pipeline and in programs that pair therapy with robotic-enabled Transcranial Magnetic Stimulation. In 2026, the company announced regulatory progress and partnerships, including collaboration with Zeta Surgical via a newly formed R&D subsidiary to pursue Combined Neuroplastic Therapy for military and first-responder settings. The organization is a relatively small biopharma team pursuing CNS therapies through established regulatory pathways.

Sign up for free to view info

Company overview Employee directory